Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Mi-Suk Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Preoperative Prediction Model for Early Recurrence of Intrahepatic Cholangiocarcinoma After Surgical Resection: Development and External Validation Study
Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park
Received December 10, 2024  Accepted February 4, 2025  Published online February 5, 2025  
DOI: https://doi.org/10.4143/crt.2024.1187    [Accepted]
AbstractAbstract PDF
Purpose
We aimed to develop a preoperative risk scoring system to predict early recurrence (ER) of intrahepatic cholangiocarcinoma (ICCA) after resection, utilizing clinical and computed tomography (CT) features.
Materials and Methods
This multicenter study included 365 patients who underwent curative-intent surgical resection for ICCA at six institutions between 2009 and 2016. Of these, 264 patients from one institution constituted the development cohort, while 101 patients from the other institutions constituted the external validation cohort. Logistic regression models were constructed to predict ER based on preoperative variables and were subsequently translated into a risk-scoring system. The discrimination performance of the risk-scoring system was validated using external data and compared to the American Joint Committee on Cancer (AJCC) TNM staging system.
Results
Among the 365 patients (mean age, 62±10 years), 153 had ER. A preoperative risk scoring system that incorporated both clinical and CT features demonstrated superior discriminatory performance compared to the postoperative AJCC TNM staging system in both the development (area under the curve [AUC], 0.78 vs. 0.68; p=0.002) and validation cohorts (AUC, 0.69 vs. 0.66; p=0.641). The preoperative risk scoring system effectively stratified patients based on their risk for ER: the 1-year recurrence-free survival rates for the low, intermediate, and high-risk groups were 85.5%, 56.6%, and 15.6%, respectively (p<0.001) in the development cohort, and 87.5%, 58.5%, and 25.0%, respectively (p<0.001) in the validation cohort.
Conclusion
A preoperative risk scoring system that incorporates clinical and CT imaging features was valuable in identifying high-risk patients with ICCA for ER following resection.
  • 180 View
  • 16 Download
Close layer
Gastrointestinal cancer
Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy
Hyun Kyung Yang, Mi-Suk Park, Kyunghwa Han, Geonsik Eom, Yong Eun Chung, Jin-Young Choi, Seungmin Bang, Chang Moo Kang, Jinsil Seong, Myeong-Jin Kim
Cancer Res Treat. 2024;56(1):247-258.   Published online August 22, 2023
DOI: https://doi.org/10.4143/crt.2023.586
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.
Materials and Methods
Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.
Results
One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).
Conclusion
“Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
  • 2,899 View
  • 168 Download
Close layer
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang
Cancer Res Treat. 2019;51(1):24-33.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2017.404
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA).
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR group were evaluated. The overall survival was compared between the two groups. The recurrence-free survival and median time to liver metastasis after curative surgery were compared between the two groups.
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31 of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free survival rates were not significantly different between the two groups (p=0.162 and p=0.721, respectively). The median time to liver metastases after curative surgery in the CT+MR group (9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a significant proportion of patients who have potentially resectable state at CT and in prolonged time to liver metastases in patients after curative surgery. Additional MRI to standard staging CT can be recommended for surgical candidates of PDA.

Citations

Citations to this article as recorded by  
  • Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
    Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, Saifudeen Abdelrahim, Karen Abboud, Adham Abdelrahim, Godsfavour Umoru, Hashem A. Rayyan, Ala Abudayyeh, Ala-Eddin Al Moustafa, Maen Abdelrahim
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
    Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2024; 62(10): e874.     CrossRef
  • S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
    Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2024; 62(10): 1724.     CrossRef
  • Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
    Felix G. Gassert, Sebastian Ziegelmayer, Johanna Luitjens, Florian T. Gassert, Fabian Tollens, Johann Rink, Marcus R. Makowski, Johannes Rübenthaler, Matthias F. Froelich
    European Radiology.2022; 32(4): 2448.     CrossRef
  • Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie
    L. Grenacher, M. Juchems, A. G. Schreyer, J. Wessling, K. I. Ringe, W. Uhl, J. Mayerle, T. Seufferlein
    Der Chirurg.2022; 93(5): 429.     CrossRef
  • Pancreatic adenocarcinoma: imaging techniques for diagnosis and management
    Jawaad Farrukh, Ravivarma Balasubramaniam, Anitha James, Sharan S Wadhwani, Raneem Albazaz
    British Journal of Hospital Medicine.2022; 83(5): 1.     CrossRef
  • S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
    Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2022; 60(06): 991.     CrossRef
  • S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
    Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
    Zeitschrift für Gastroenterologie.2022; 60(11): e812.     CrossRef
  • The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
    Hyungjin Rhee, Mi-Suk Park
    Korean Journal of Radiology.2021; 22(1): 23.     CrossRef
  • A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma
    Ji Eun Lee, Seong Hyun Kim, Soon Jin Lee, Seo-Youn Choi, Sunyoung Lee, Bo Ra Lee
    Journal of the Korean Society of Radiology.2021; 82(3): 638.     CrossRef
  • СT and MRI in the assessment of resectable and borderline resectable pancreatic tumors
    A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzawa, I. S. Zheleznyak, G. E. Trufanov, V. V. Ryazanov, V. A. Krasovskaya, A. B. Kotiv, A. D. Kazakov
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2021; 26(1): 34.     CrossRef
  • European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
    Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet
    Cancer Treatment Reviews.2021; 99: 102208.     CrossRef
  • ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
    Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Masayuki Sho, Masaji Tani, Ippei Matsumoto, Suguru Yamada, Ryosuke Amano, Hirochika Toyama, Yo-ichi Yamashita, Takeshi Gocho, Kazuto Shibuya, Minako Nagai, Hiromitsu Maehira, Keiko Kamei, Go Ohira, Yoshihiro Shi
    Trials.2021;[Epub]     CrossRef
  • Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report
    Danling Guo, Chao Chen, Sangying Lv, Guanzuan Wu, Wei Shi, Huaifeng Li, Hongjie Hu
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC
    Min Woo Kim, Hani Koh, Jee Ye Kim, Suji Lee, Hyojung Lee, Young Kim, Ho Kyoung Hwang, Seung Il Kim
    International Journal of Molecular Sciences.2021; 22(24): 13621.     CrossRef
  • Imaging and Management of Pancreatic Cancer
    Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
    Seminars in Ultrasound, CT and MRI.2020; 41(2): 139.     CrossRef
  • DUPLICATE: Imaging and Management of Pancreatic Cancer
    Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
    Seminars in Ultrasound, CT and MRI.2019;[Epub]     CrossRef
  • 10,780 View
  • 319 Download
  • 18 Web of Science
  • 17 Crossref
Close layer
Magnetic Resonance Imaging for Colorectal Cancer Metastasis to the Liver: Comparative Effectiveness Research for the Choice of Contrast Agents
Nieun Seo, Mi-Suk Park, Kyunghwa Han, Kyung Ho Lee, Seong Ho Park, Gi Hong Choi, Jin-Young Choi, Yong Eun Chung, Myeong-Jin Kim
Cancer Res Treat. 2018;50(1):60-70.   Published online March 14, 2017
DOI: https://doi.org/10.4143/crt.2016.533
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to compare the diagnostic performance and early recurrence rate between gadoxetic acid–enhanced magnetic resonance imaging (Gd-EOB-MRI) and magnetic resonance imaging (MRI) with extracellular contrast agent (ECA-MRI) for evaluating hepatic lesions in colorectal cancer.
Materials and Methods
Between 2005 and 2010, 418 colorectal cancer patients with both preoperative computed tomography (CT) and liver MRI were retrospectively reviewed. Image analysis was based on initial radiologic reports, and diagnostic performance was assessed based on the area under the receiver operating characteristic curve (AUROC). The early intrahepatic recurrence rate within 6 months was then evaluated.
Results
Overall, 291 and 127 patients underwent Gd-EOB-MRI and ECA-MRI, respectively. The AUROCs were not significantly different between Gd-EOB-MRI (0.990; 95% CI, 0.980 to 0.999) and ECA-MRI (0.985; 95% CI, 0.968 to 1.000; p=0.836). When compared with CT alone, ECA-MRI detected additional 21 lesions in 14 patients (14/127, 11.0%), whereas Gd-EOB-MRI detected 56 lesions in 33 patients (33/291, 11.3%) without a significant difference between two MRI groups (p=0.331). The early recurrence rate in the ECA-MRI (28.6%) was significantly higher than that in the Gd-EOB-MRI (11.6%) for patients who underwent hepatic resection (p=0.031).
Conclusion
Gd-EOB-MRI is potentially better than ECA-MRI for decreasing the early intrahepatic recurrence rate, although the two MRI modalities showed comparable diagnostic performance in colorectal cancer patients.

Citations

Citations to this article as recorded by  
  • Clinical performance of a simulated abbreviated liver magnetic resonance imaging in combination with contrast-enhanced computed tomography for the baseline evaluation of the liver in patients with colorectal cancer
    F. Castagnoli, S.J. Withey, M. Konidari, I. Chau, A. Riddell, J. Shur, C. Messiou, D.M. Koh
    Clinical Radiology.2025; 80: 106743.     CrossRef
  • Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation
    Ruijun Zhang, Zixuan He, Jian Zhu, Xiaochen Yuan, Guoheng Huang, Chi-Man Pun, Jianhong Peng, Junzhong Lin, Jian Zhou
    Physics in Medicine & Biology.2022; 67(20): 205008.     CrossRef
  • Diagnostic Performance of Deep Learning-Based Lesion Detection Algorithm in CT for Detecting Hepatic Metastasis from Colorectal Cancer
    Kiwook Kim, Sungwon Kim, Kyunghwa Han, Heejin Bae, Jaeseung Shin, Joon Seok Lim
    Korean Journal of Radiology.2021; 22(6): 912.     CrossRef
  • Application of intraoperative ultrasound in liver surgery
    Ya-Wei Xu, Hong Fu
    Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 501.     CrossRef
  • Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
    Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang
    Cancer Research and Treatment.2019; 51(1): 24.     CrossRef
  • Abbreviated Gadoxetic Acid–enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation
    Jeong Woo Kim, Chang Hee Lee, Yang Shin Park, Jongmee Lee, Kyeong Ah Kim
    Radiology: Imaging Cancer.2019; 1(1): e190006.     CrossRef
  • Intraoperative Ultrasound Staging for Colorectal Liver Metastases in the Era of Liver-Specific Magnetic Resonance Imaging: Is It Still Worthwhile?
    Serena Langella, Francesco Ardito, Nadia Russolillo, Elena Panettieri, Serena Perotti, Caterina Mele, Felice Giuliante, Alessandro Ferrero
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Capabilities of 18F-FDG PET/CT in the differential diagnosis of colorectal liver metastases
    M. S. Tlostanova, A. L. Dolbov, A. A. Stanzhevskii
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2019; 24(4): 18.     CrossRef
  • Imagerie par résonance magnétique dans le bilan local préopératoire des cancers du rectum
    M. Djelouah, C. Durot, S. Deguelte-Lardière, J. Cohen, A. Devie, L. Protin-Catteau, C. Hoeffel
    EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2019; 37(2): 1.     CrossRef
  • 12,210 View
  • 356 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
Yeo-Eun Kim, Bio Joo, Mi-Suk Park, Sang Joon Shin, Joong Bae Ahn, Myeong-Jin Kim
Cancer Res Treat. 2016;48(4):1210-1221.   Published online March 17, 2016
DOI: https://doi.org/10.4143/crt.2015.374
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and Methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests.
Results
The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.

Citations

Citations to this article as recorded by  
  • Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights
    Geetika Kaur, Bipradas Roy
    Biomedicines.2024; 12(4): 827.     CrossRef
  • Current trends in the characterization and monitoring of vascular response to cancer therapy
    Binita Shrestha, Noah B Stern, Annie Zhou, Andrew Dunn, Tyrone Porter
    Cancer Imaging.2024;[Epub]     CrossRef
  • Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases
    Martina Caruso, Arnaldo Stanzione, Anna Prinster, Laura Micol Pizzuti, Arturo Brunetti, Simone Maurea, Pier Paolo Mainenti
    World Journal of Gastroenterology.2023; 29(3): 521.     CrossRef
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition
    Brandon M. Bordeau, Joseph Ryan Polli, Ferdinand Schweser, Hans Peter Grimm, Wolfgang F. Richter, Joseph P. Balthasar
    International Journal of Molecular Sciences.2022; 23(2): 679.     CrossRef
  • The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids
    Sarah Line Bring Truelsen, Nabi Mousavi, Haoche Wei, Lucy Harvey, Rikke Stausholm, Erik Spillum, Grith Hagel, Klaus Qvortrup, Ole Thastrup, Henrik Harling, Harry Mellor, Jacob Thastrup, Christina L. Addison
    PLOS ONE.2021; 16(7): e0253258.     CrossRef
  • [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
    Rohini Sharma, Pablo Oriol Valls, Marianna Inglese, Suraiya Dubash, Michelle Chen, Hani Gabra, Ana Montes, Amarnath Challapalli, Mubarik Arshad, George Tharakan, Ed Chambers, Tom Cole, Jingky P. Lozano-Kuehne, Tara D. Barwick, Eric O. Aboagye
    European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(5): 1239.     CrossRef
  • Combination of DCE‐MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma
    Changmin Liu, Roger Sun, Jing Wang, Fangling Ning, Zhenbo Wang, Judong Luo, Shaoshui Chen, Shuanghu Yuan, Enzo Terreno
    BioMed Research International.2020;[Epub]     CrossRef
  • Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging
    Pier Paolo Mainenti, Arnaldo Stanzione, Salvatore Guarino, Valeria Romeo, Lorenzo Ugga, Federica Romano, Giovanni Storto, Simone Maurea, Arturo Brunetti
    World Journal of Gastroenterology.2019; 25(35): 5233.     CrossRef
  • Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients
    Matteo Morotti, Prashanth Hari Dass, Adrian L. Harris, Simon Lord
    European Journal of Drug Metabolism and Pharmacokinetics.2018; 43(2): 137.     CrossRef
  • Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
    Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile
    BMC Cancer.2018;[Epub]     CrossRef
  • Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases
    Pavitra Kannan, Warren W. Kretzschmar, Helen Winter, Daniel Warren, Russell Bates, Philip D. Allen, Nigar Syed, Benjamin Irving, Bartlomiej W. Papiez, Jakob Kaeppler, Bosjtan Markelc, Paul Kinchesh, Stuart Gilchrist, Sean Smart, Julia A. Schnabel, Tim Mau
    Clinical Cancer Research.2018; 24(19): 4694.     CrossRef
  • Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy
    Marie Mogensen, Martin Hansen, Birthe Henriksen, Thomas Axelsen, Ben Vainer, Kell Osterlind, Michael Nielsen
    Diagnostics.2017; 7(2): 35.     CrossRef
  • Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis
    Simonetta Geninatti Crich, Enzo Terreno, Silvio Aime
    Advanced Drug Delivery Reviews.2017; 119: 61.     CrossRef
  • 10,286 View
  • 147 Download
  • 14 Web of Science
  • 13 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP